Stryker (NYSE:SYK) Price Target Cut to $304.00 by Analysts at BTIG Research

Stryker (NYSE:SYK) had its price objective decreased by BTIG Research from $316.00 to $304.00 in a research note released on Friday morning,Benzinga reports. BTIG Research currently has a buy rating on the medical technology company’s stock.

Other equities analysts have also issued reports about the stock. Piper Sandler cut their target price on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Weiss Ratings restated a “hold (c)” rating on shares of Stryker in a research report on Thursday. Wolfe Research downgraded Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. BMO Capital Markets reissued an “outperform” rating and issued a $317.00 price target on shares of Stryker in a report on Wednesday, September 9th. Finally, Argus set a $370.00 price target on shares of Stryker in a research report on Thursday, July 9th. Sixteen equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $355.84.

Stryker Stock Performance

Shares of SYK opened at $291.56 on Friday. Stryker has a one year low of $267.00 and a one year high of $389.33. The stock has a market cap of $111.83 billion, a P/E ratio of 31.05, a P/E/G ratio of 2.01 and a beta of 0.78. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock has a 50-day moving average of $292.83 and a two-hundred day moving average of $324.51.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing the consensus estimate of $3.55 by ($0.03). Stryker had a net margin of 13.78% and a return on equity of 23.83%. The business had revenue of $6.52 billion during the quarter, compared to analysts’ expectations of $6.62 billion. During the same period last year, the company earned $3.19 earnings per share. The firm’s revenue was up 7.6% on a year-over-year basis. As a group, research analysts predict that Stryker will post 14.93 EPS for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend was Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 300,000 shares of Stryker stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the sale, the director directly owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. The trade was a 11.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider owned 6,102 shares of the company’s stock, valued at $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 351,267 shares of company stock valued at $118,197,701 over the last 90 days. 4.60% of the stock is owned by insiders.

Institutional Trading of Stryker

A number of large investors have recently modified their holdings of SYK. Community Bank & Trust Waco Texas raised its holdings in Stryker by 2.3% in the 2nd quarter. Community Bank & Trust Waco Texas now owns 1,395 shares of the medical technology company’s stock valued at $439,000 after acquiring an additional 31 shares in the last quarter. Cornerstone Financial Management LLC raised its stake in shares of Stryker by 66.0% in the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after buying an additional 31 shares in the last quarter. NWF Advisory Services Inc. boosted its position in shares of Stryker by 2.3% during the 2nd quarter. NWF Advisory Services Inc. now owns 1,472 shares of the medical technology company’s stock valued at $463,000 after acquiring an additional 33 shares in the last quarter. Harold Davidson & Associates Inc. boosted its position in shares of Stryker by 0.4% during the 1st quarter. Harold Davidson & Associates Inc. now owns 8,668 shares of the medical technology company’s stock valued at $2,848,000 after acquiring an additional 34 shares in the last quarter. Finally, Private Harbour Investment Management & Counsel LLC raised its position in Stryker by 0.9% in the second quarter. Private Harbour Investment Management & Counsel LLC now owns 3,927 shares of the medical technology company’s stock worth $1,236,000 after purchasing an additional 34 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly revenue increased 7.6% year over year to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also cited strength in MedSurg, margin improvement and continued investment in robotic surgery. Stryker reports third quarter 2026 operating results
• Positive Sentiment: Despite lower forecasts, several analysts remain constructive. Barclays maintained an overweight rating with a $365 target, while Citizens JMP kept “market outperform” at $390 and RBC retained “outperform” with a $375 target. RBC cuts price target on Stryker
• Neutral Sentiment: Analyst sentiment has become more divided. Citigroup cut its target to $315 but kept a buy rating, BTIG reduced its target to $304 while maintaining buy, and TD Cowen lowered its target to $290 with a hold rating. Canaccord also downgraded the shares to hold and cut its target to $300.
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 and revenue of $6.52 billion missed consensus estimates of $3.55 and $6.62 billion, respectively. Stryker Q3 earnings and revenues lag estimates
• Negative Sentiment: Stryker cut its 2026 forecast to 6.5%-7.0% organic sales growth and $14.80-$14.90 adjusted EPS, from previous ranges of 8.3%-9.3% and $14.95-$15.10. Weaker joint-replacement demand, supply disruptions and ongoing peripheral-vascular manufacturing problems are weighing on expectations. SYK stock outlook cut

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.